The FDA awarded Oculus Innovative Sciences, Inc. 510(k) clearance for its new post-dermal-procedures product. Under the supervision of a healthcare professional, the product is intended for the removal of foreign material including microogranisms and debris from post­dermal procedures.

“Within my practice I utilize the Microcyn Technology (hypochlorous acid or HOCl) post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections. I find these HOCl products to be safer, non-cytotoxic, and a more effective alternative to povidone-iodine and chlorhexidine. Now, with this approval from the FDA, I believe my peers will benefit from adding Microcyn-based products to their treatment protocols,” said Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, the Laser & Rejuvenation Center and Tennessee Clinical Research Center, all located in Nashville, TN. 

Oculus’ dermatology division, IntraDerm, will begin marketing the post­dermal-procedures product in the United States beginning in March 2017.